Early Toronto experience with new standards for industry-sponsored clinical research: A progress report

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 4, 2002, Pages 453-456

  Naylor, C David ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DRUG APPROVAL; DRUG INDUSTRY; MEDICAL ETHICS; MEDICAL RESEARCH; NOTE; SAFETY; STANDARD; TEACHING HOSPITAL;

EID: 0036169082     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Conflict of interest in the debate over calcium-channel antagonists
2. Industry-sponsored clinical research: A double-edged sword
3. The uncertainty principle and industry-sponsored research
4. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drug in the treatment of arthritis
5. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis
6. Industry-sponsored research
7. Long-suppressed study finally sees light of day
8. Secrecy dispute pits Brown researcher against company
9. Thyroid storm
10. Academia and industry: Lessons from the unfortunate events in Toronto
11. Sponsorship, authorship, and accountability
12. Redundancy, disaggregation, and the integrity of medical research
13. Should there be early publication of ancillary studies prior to the first primary report of an unblinded randomized clinical trial?